Clinical Trial Update: Effect of OC000459 on Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial of OC000459 for moderate-to-severe atopic dermatitis and notes that results were posted in December 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• OC000459

Snippet

Sponsor: Atopix Therapeutics, Ltd. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2016-12-08